{"id":937808,"date":"2026-02-18T08:19:54","date_gmt":"2026-02-18T13:19:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/"},"modified":"2026-02-18T08:19:54","modified_gmt":"2026-02-18T13:19:54","slug":"marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/","title":{"rendered":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, Feb.  18, 2026  (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36<sup>th<\/sup> Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026.<\/p>\n<p align=\"justify\">\n        <strong>Presentation Details: <\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Event:<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Oppenheimer 36<\/strong><br \/>\n            <sup><br \/>\n              <strong>th<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Healthcare Life Sciences Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Date: <\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Wednesday, February 25, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Time: <\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">8:00 \u2013 8:30 a.m. EST<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Track: <\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">Track 3<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Webcast Link: <\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"https:\/\/ir.markertherapeutics.com\/news-events\/events-presentations\/\" rel=\"nofollow\" target=\"_blank\">\u201cEvents and Presentations\u201d<\/a> section on Marker\u2019s IR website<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <br \/>During the conference, Dr. Vera and Marker\u2019s management team will conduct one-on-one meetings with registered investors to discuss the Company\u2019s progress across its Multi-Antigen Recognizing (MAR) T cell platform.<\/p>\n<p align=\"justify\">To view the event online, investors can register and access the webcast through Marker\u2019s Investor Relations website under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rHWQbd2TK0z2f_IZ_rc-nU6MBa5ZJlN4MfqGml5U_Zv1y0hDtWiH7RgysDoPwwts7RHdD6IdJ9HPlfVa6j9_YNwSlR127j_aJpHnbHB21fexhK6W_CXok5ZR6_dmvjyNGtTE8DV1nrNOjbjfzzGH1vUD-2D0tu7sVQ68kUx88P8=\" rel=\"nofollow\" target=\"_blank\">\u201cEvents and Presentations\u201d<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Marker Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Marker Therapeutics, Inc.\u00a0is a\u00a0Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at\u00a0Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company\u2019s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker\u2019s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker\u2019s unique T cell platform is strengthened by non-dilutive funding from\u00a0U.S.\u00a0state and federal agencies supporting cancer research.<\/p>\n<p align=\"justify\">To receive future press releases via email, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HfND6s73PblW1c3bvGLZeLEfxiS3s70sQN09eMFPqmpaqwhp7Kn_RT9TDjr-sxaumyHbI0g2wn21V9iR1SE_9nDxuBjnk-UPn37nuE3-DlXQGjpXtXDeGZ2N5PHc-5wZsElM46I6QYtiQ8dBgPFEd0F9WMIixZuqauD4calFRcYPAabX0iJ6yFEwPD-ad9C2L4SnlNKAhGNLG_ReOVVFTzAHqBVtzywWsYQmc_O2_4i_FNPYsWVf0EE2Opu9Hvyn1Ft2P3YZdNvzy9lhYHNf7qhd3ytULxl-A74cKoPe5ARvd8lrsrB9soXNgM-pz4mD8AXJ9Z4KobXk5Y3Gcat69fbVPHW9p7zG6v_qHX4U5JkvRRWwklfPHnjfSfAEt_dQ0sH_MR2CJl3VKNEdvWdiHQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company\u2019s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are \u201cforward-looking statements.\u201d Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi- antigen recognizing T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company\u2019s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.<\/p>\n<p>\n        <strong>Investor and Media Contact<\/strong><br \/>\n        <br \/>Marker Therapeutics, Inc.<br \/>+1 (713) 400-6400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gjtl2Ju63IGUr6hnAsR1J-XEFDjoKxXPOhFAuMkKQinr3zxQbg1DcZNkiRM1HM0cNFABj22aw165cXFWzSzVPfX-6W3RUm_htIJf1jR2nTuZmifZII0oT1G3OIWKlzdBa3xba7zSUr-NYC2QdKlVNVnEhfkvmGez8kQxjfYJr5xeh-k0h7_D-7IKLjU-guXw-TFQJVE5Aa7Kj4FtjlQ5ydFmSi1uKRF5fOmZTf4cuIgega-VOYvzHjC2rL3Ik5DTE0mtLppFlKmbISAFXcRALoenuwBXxcP7hi4U_N3SuuUvXq6ZHEM8PG1nvbnKGlymNdDrRfIgFmGZisy0D9jfWGUSY2Xx7Cgm5oca1ik0kotWnxCDDQDV8Wbl3i2eer6UT4xR0pLDoeY-Ya8Vc11jtSp51QZWI7PhR1e_EHb_TyE2mkoKtHmdjvyX_2tpGBl9rfQE94BmjfYj9pbiEVoobYY056xTRVHwa8yY6ifmvKNoyLiz9waMWCjjNGJQUWCNvdCEIiBQc7uJEdG7HJ2cyu0Lh0u8T8CK2VM1rje8mnh1Lpp7Uk1uAMFxB-72UD0yf-v1628E-_bZCq7ZorEOsC67naKoQVDBlqxPRQDrfvnYl0kC0sq5OHMW4Hm7K1gWY9XWol9iFenbDFpcdpDj1ZusQMuFqw2tE4zRKFHhlpDQJ65tOpOpDYS4h5ixhOdGvaQ1WRRkxsHf4crBx0SOe0YnHiHvGZ_PQXEQHNvGhMKBBaUSNZSLgOWrqVXRPwEdoeCWIJBJDd-5HQV7N60v1chg17X9weDr3DFZEO6NOBigwXSm1PKwPtWTF7cy4Qth7rmFUEgGqasAjJ9PuAwRNlKwEeQhKpoZHKXKctnlXCIgGyTjZF_Xk_HNr4r3mqSBbzqcBdhtTubDM4XjSWk7F0pXD1ms8lsIhEavsqJNUS8pyH0TGQShzA5poQp6_UdEmOgK8vTDlhixk29DAcy8tjm6bMweUdynvu4-NnQ0EY4BBZRA4-457PTBCL11gtnSNrKBsNyW4HxiMAOuPMXotg==\" rel=\"nofollow\" target=\"_blank\">investor.relations@markertherapeutics.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWY1ODhjOTMtNjg2Yy00OTVlLThhODAtOGE4MTBiMTE2MzIwLTExOTkyNzEtMjAyNi0wMi0xOC1lbg==\/tiny\/Marker-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 \u2013 8:30 a.m. EST Track: Track 3 Webcast Link: \u201cEvents and Presentations\u201d section on Marker\u2019s IR website During the conference, Dr. Vera and Marker\u2019s management team will conduct one-on-one meetings with registered investors to discuss the Company\u2019s progress across &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937808","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 \u2013 8:30 a.m. EST Track: Track 3 Webcast Link: \u201cEvents and Presentations\u201d section on Marker\u2019s IR website During the conference, Dr. Vera and Marker\u2019s management team will conduct one-on-one meetings with registered investors to discuss the Company\u2019s progress across &hellip; Continue reading &quot;Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T13:19:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference\",\"datePublished\":\"2026-02-18T13:19:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/\"},\"wordCount\":555,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/\",\"name\":\"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\",\"datePublished\":\"2026-02-18T13:19:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk","og_description":"HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc.\u00a0(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 \u2013 8:30 a.m. EST Track: Track 3 Webcast Link: \u201cEvents and Presentations\u201d section on Marker\u2019s IR website During the conference, Dr. Vera and Marker\u2019s management team will conduct one-on-one meetings with registered investors to discuss the Company\u2019s progress across &hellip; Continue reading \"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-18T13:19:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference","datePublished":"2026-02-18T13:19:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/"},"wordCount":555,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/","name":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=","datePublished":"2026-02-18T13:19:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjYwNiM3NDMxNTUwIzIxODc3MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937808"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937808\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}